export default function NeuropeptideSOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Neuropeptide S is a brain signaling molecule that produces wakefulness and reduces anxiety
        simultaneously in animal studies &mdash; an unusual combination that&rsquo;s attracted real
        scientific interest. There is no therapeutic formulation that exists, no human safety data,
        and no community use protocol. This page is for people curious about the biology, not people
        trying to source a compound.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Average Person &mdash; anxiety and sleep research curious</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I heard Neuropeptide S is connected to anxiety and panic &mdash; could this be relevant to what I&rsquo;m dealing with?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re interested</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The genetic connection to panic disorder is real and established</strong><br />Genetic studies have found that variations in the gene for the Neuropeptide S receptor are associated with panic disorder and anxiety disorders in humans. This isn&rsquo;t a tenuous animal-model claim &mdash; it&rsquo;s human genetic epidemiology. For someone who has an anxiety disorder and is trying to understand the biology of why some people are more vulnerable than others, this is genuinely informative context.</li>
          <li><strong>The wakefulness-plus-anxiolytic dual profile is unusual and interesting</strong><br />Most stimulating compounds increase anxiety. Most anxiolytics cause sedation. Neuropeptide S&rsquo;s profile in animals &mdash; simultaneously more awake and less anxious &mdash; is pharmacologically unusual and conceptually attractive to people who experience anxiety-driven fatigue or the kind of wired-and-tired pattern common in chronic stress.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The genetic association with panic disorder does not mean that taking Neuropeptide S would help with anxiety &mdash; in fact, the pharmacological research suggests that blocking the receptor (not activating it) might be the therapeutic direction for panic disorder. There is no Neuropeptide S product to buy, no established dose, no route of administration known to work in humans, and no community experience to draw on. If you have anxiety or panic disorder, established options exist &mdash; SSRIs, CBT, and compounds like Selank that at least have some human data. Looking into Neuropeptide S as a treatment option is not where the answer is. <strong>Net: real biology, zero actionable compound for personal use.</strong></p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Curious Reader &mdash; came across it somewhere</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I saw Neuropeptide S mentioned in a discussion about novel anxiolytic peptides &mdash; is this something that&rsquo;s actually being used?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re interested</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It sounds like a cutting-edge novel compound</strong><br />Neuropeptide S was only identified as a functional signaling molecule in 2004. It&rsquo;s genuinely recent neuroscience &mdash; the receptor it acts on (NPSR1) is a real, characterized receptor with clear genetic relevance to anxiety. The compound has all the surface characteristics of something that should be in the community peptide conversation: novel mechanism, interesting dual effects, genetic human relevance.</li>
          <li><strong>The science behind it is legitimate and interesting</strong><br />NPSR1 genetics research is published in reputable journals and has been replicated across multiple anxiety disorder populations. Neuropeptide S itself is a valid research tool in animal neuroscience labs studying anxiety circuits. The underlying science is real &mdash; it&rsquo;s the translation to usable human compound that doesn&rsquo;t exist.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The gap between &ldquo;interesting receptor biology&rdquo; and &ldquo;usable compound&rdquo; is enormous for Neuropeptide S. Even if someone sells something labeled NPS, there is no reference human dose, no established delivery route that reaches the brain from peripheral injection, and no community experience to calibrate against. The dose-response in animal models is complex &mdash; the same compound can be anxiolytic or anxiogenic depending on dose and brain region. That complexity hasn&rsquo;t been untangled for humans at all. <strong>Net: real science, not a real community compound; the interesting pharmacological program here is NPSR1 antagonists for panic disorder, which are in early drug development &mdash; and those block the receptor, not activate it.</strong></p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; NPSR1 pharmacology and anxiety neuroscience</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to understand what NPSR1 biology tells us about anxiety circuits and whether the therapeutic direction is agonism, antagonism, or something else entirely.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re interested</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The directionality question is pharmacologically interesting and unresolved</strong><br />The NPSR1 genetics associate increased receptor sensitivity with panic disorder &mdash; which suggests the receptor is involved in anxiety amplification. But Neuropeptide S in animal models often shows anxiolytic effects when administered. This apparent paradox (higher receptor sensitivity correlates with more anxiety, but activating the receptor acutely reduces anxiety in animals) maps onto the complex autoregulation that characterizes many CNS neuropeptide systems and is genuinely worth thinking through carefully rather than assuming agonism is beneficial.</li>
          <li><strong>NPSR1 antagonists are the actual therapeutic program &mdash; and it&rsquo;s early but real</strong><br />Based on the genetics, pharmaceutical researchers have pursued NPSR1 antagonists for panic disorder &mdash; blocking a receptor whose hyperactivity associates with anxiety vulnerability. This is early-stage but scientifically grounded. For a biohacker tracking the anxiety pharmacology frontier, following the NPSR1 antagonist development pipeline is where the legitimate clinical translation is happening, not in exogenous NPS.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Even if peripheral Neuropeptide S injection were something that could work pharmacologically, the blood-brain barrier problem is real: a 20-amino-acid peptide administered subcutaneously needs to cross into the CNS to reach NPSR1 in the brain regions that matter for anxiety and wakefulness. That penetration is not established. Intracerebral or intracerebroventricular delivery (how the animal studies work) is not a community-accessible route. The interesting scientific work on this system is happening in drug development labs, not in self-experimentation, and for good reason. <strong>Net: the pharmacology is worth understanding; there is no usable compound and no safe path to experimental use.</strong></p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Neuropeptide S is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>A compound you can buy, take, or inject &mdash; no therapeutic formulation exists anywhere</li>
              <li>Something with a community use protocol, established dose, or track record</li>
              <li>An anxiolytic you can use based on genetic associations &mdash; the pharmacological direction for panic disorder may be receptor antagonism, not agonism</li>
              <li>Safely deliverable to brain targets from subcutaneous injection &mdash; BBB penetration is not established for this peptide</li>
              <li>Something with characterized dose-response in humans in any context</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>NPSR1 genetics are genuinely linked to panic disorder and anxiety vulnerability in humans</li>
              <li>The simultaneous wakefulness and anxiolytic profile in animals is pharmacologically unusual</li>
              <li>Active NPSR1 antagonist drug development programs represent the legitimate clinical translation of this biology</li>
              <li>A useful example of how interesting receptor biology doesn&rsquo;t automatically produce a usable therapeutic compound</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
